Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

NCT01505062 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01505062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01505062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
March 26, 2012
Completion date
August 16, 2019
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa, usher syndrome